Skip to main content
OpenTrials
Completed

NCT Number: NCT02561585

LEO 124249 Ointment in the Treatment of Alopecia Areata

This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alopecia Areata Alopecia Hair Diseases Hypotrichosis Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Northwestern University, Evanston, Illinois, United States

Loading trial locations.

About this study

The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects with alopecia areata, to evaluate the safety of this treatment, to evaluate hair regrowth, to determine subject quality of life, and to explore disease mechanism and its biomarkers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects must have signed and dated informed consent after receiving verbal and written information about the clinical trial.
  • Subjects with unequivocal clinical diagnosis of moderate to severe scalp alopecia areata (patch type, totalis, universalis), as determined by the (sub) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline).
  • Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit.
  • Subject must accept to not cut hair in the treated scalp areas during the trial.

Exclusion criteria

  • Females who are pregnant or are breast feeding.
  • Current signs of spontaneous hair regrowth.
  • Diffuse type alopecia areata.
  • Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig stage II and III)
  • Subjects with changed or expected changes in medication for thyroid disease within 6 month before Visit 1 (screening) or during the trial.
  • Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids, or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).

Treatment and study plan

LEO 124249

Drug

Other names: LEO 124249 Ointment

Vehicle

Other

Other names: LEO 124249 Vehicle

Primary outcomes

  1. Change in Severity of Alopecia Areata Tool (SALT) Score

    Time frame: From baseline (Day 1) to Week 12 (Day 84)

    The SALT score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

Secondary outcomes

  1. Summary of Absolute SALT Score

    Time frame: At baseline (Day 1), Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss.

    Summary of observed values of the absolute SALT score.

  2. Summary of Change in SALT Score

    Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

  3. Summary of Relative Change in SALT Score

    Time frame: From baseline (Day 1) to Week 4 (Day 28), Week 8 (Day 56), and Week 12 (Day 84)

    The SALT (Severity of Alopecia Areata Tool) score indicates the sum area of scalp with hair loss and ranges from 0 - 100 (min-max), with higher scores indicating more hair loss. A negative change in SALT score indicates lesser (improvement) hair loss while positive high scores indicate more (worsening) hair loss.

  4. Percentage of Patients Who Achieve 50% Improvement in the SALT Score

    Time frame: At Week 12 (Day 84)

    The event of having at least 50% reduction in SALT score at Week 12 (Day 84) as compared to baseline (Day 1)

  5. Hair Length

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Hair length measured in millimeters.

  6. Hair Growth Rate

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Change in hair length measured in millimeters per day.

  7. Relative Hair Thickness

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Thickness relative to participant's normal scalp hair. Relative assessment not applicable for participants with alopecia areata totalis and universalis.

  8. Hair Type

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Hair type being either vellus hair or terminal hair. Hair type is not applicable for participants with alopecia areata totalis and universalis.

  9. Hair Color

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Absolute color of hair. Hair color is not applicable for alopecia areata totalis and universalis.

  10. Global Assessment of Overall Hair Regrowth Compared to Baseline

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    Based on standardized photographs

  11. Participant's Global Assessment of Hair Regrowth

    Time frame: At Week 4 (Day 28), Week 8 (Day 56) and Week 12 (Day 84)

    The participant will assess the hair regrowth before the investigator does any assessments of hair regrowth.

  12. Subcategory and Total Score of the Alopecia Areata Quality of Life Questionnaire (AA-QLI)

    Time frame: At baseline (Day 1) and at Week 12 (Day 84)

    The scale includes 21 questions measuring the degree to which the patient was affected by the AA in the last month, scored from 1 (not affected at all) to 4 (highly affected).

    The AA-QLI transformed scores for each of the subcategories 'subjective symptoms', 'relationship' and 'objective signs' ranging from (min-max) 9-36, 9-36, and 3-12. Total score ranges from 0-84.

    Low score indicating that the participant was least affected by AA.

  13. Treatment Satisfaction Questionnaire for Medication Score

    Time frame: At Week 12 (Day 84)

    The Treatment Satisfaction Questionnaire for Medication (TSQM II) is a validated, general measure of treatment satisfaction for medication - accounting for effectiveness, side effects, convenience, and global satisfaction - that is comparable across medication types and patient conditions.

    The individual derived score for each of the 4 dimensions (effectiveness, side effects, convenience, and global satisfaction) of the TSQM II questionnaire ranged from 0-100, with a higher score indicating greater satisfaction to treatment.

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Official study title

Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Sep 28, 2015
Registry last updated
Mar 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.